Pelago Bioscience

Pelago Bioscience AB provides and develops the patented Cellular Thermal Shift Assay (CETSA^®) for use in determination and quantification of drug–target interactions. The company delivers in situ target engagement studies to accelerate drug discovery and diagnostics development. CETSA^® provides a quantitative measure of Target Engagement and biophysical readout of affinity, adding real value to existing efficacy assays.